News
-
Janssen Pharmaceutical has submitted an MAA to the EMA for its esketamine nasal spray for the treatment of treatment-resistant depression in adults with major depressive disorder, the company said. Janssen submitted an NDA for the… Read more . . .
-
Organizers of DDL 2018 say that they are expecting over 800 OINDP specialists to attend this year’s iteration of the Drug Delivery to the Lungs meeting, to be held December 12-14 in Edinburgh, UK. According… Read more . . .
-
KAER Biotherapeutics has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute of the National Institutes of Health for development of a device… Read more . . .
-
US-based pharmaceutical supply services firm Experic is expanding its focus with the appointment of DPI expert Justin Lacombe as Director of Pharmaceutical Development and Manufacturing Services and the announcement that the company has leased a… Read more . . .
-
According to Medical Developments International (MVP), Daiichi Sankyo will pay up to $32.5 million for the rights to distribute MVP’s Penthrox methoxyflurane inhaler in China, Vietnam, and Thailand. The deal includes $15 million up front… Read more . . .
-
According to California-based start-up CounterAct, the FDA has approved of the company’s approach regarding potential approval of its naloxone nasal spray cap. The CounterAct cap is a plastic device that snaps onto the top of… Read more . . .
-
Swiss CDMO Micro-Sphere has announced the addition of new DPI capsule filling capacity with a new MG2 Tekna filling machine in a dedicated, humidity-controlled cleanroom at its facility near Lugano. The company also has added… Read more . . .
-
Aptar Pharma has announced that it will officially launch its new PureHale aerosol device at CPhI Worldwide. Purehale, a bag-on-valve “nebulizer-like device,” is a finalist for the CPhI Pharma Awards in the drug delivery device… Read more . . .
-
The FDA has approved Insmed’s amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in a limited population of patients. Arikayce, which Insmed had recently… Read more . . .
-
United Therapeutics will pay Samumed $10 million up front and up to $340 million in milestones, plus royalties, for North American rights to Samumed’s SM04646, a Wnt signaling pathway inhibitor that in in Phase 1… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany